DYNAMICS OF DEVELOPMENT OF CHONDROITIN SULFATE AND THE PLACE OF GLYCOSAMINOGLYCAN-PEPTIDE COMPLEXES IN THE TREATMENT OF OSTEOARTHRITIS

Dubkova A.G. ¹, Krylova A.S.¹, Bortkevych O.P. ², Tsymbaliuk T.S.¹

• ¹Shupyk National Healthcare University of Ukraine, Kyiv
• ²State Institution National Scientific Center «M.D. Strazheska Institute of Cardiology» National Academy of Medical Sciences of Ukraine, Kyiv

Summary. Objectives. Glycosaminoglycan-peptide complex (GPC) is a slow-release anti-inflammatory agent that has complex anti-inflammatory and metabolic effects. GPC has been successfully used in the treatment of osteoarthritis (OA) for several decades. The agent now returns again to the clinical practice. Aim. The aim of this article was to review the literature and highlight current aspects of the use of chondroitin sulfate and the place of glycosaminoglycan-peptide complexes in the treatment of OA. Methods. The scientific search in printed and electronic editions, scientific search databases Medline and PubMed using methods of analysis, comparison and generalization of information data is carried out. Relevant articles on the use of chondroitin sulfate and glycosaminoglycan-peptide complexes in the treatment of OA have been identified and reviewed. Results. The article covers the characteristics of the six main classes of glycosaminoglycans and the main mechanisms of their action. The structural composition and influence on the quality of the drug impurities are described. Published randomized placebo-controlled studies (RCTs) evaluating the symptomatic effects of COD have been reported. The authors of the review studied the current recommendations of the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) for the diagnosis and treatment of OA.The article discusses the issues of drug therapy of OA, in particular the possibility of using chondroitin sulfate and its pleiotropic effects. New data on the use of glycosaminoglycan-peptide complexes in the treatment of OA and new directions of their application are analyzed. Conclusions. The use of glycosaminoglycan-peptide complexes in patients with OA contributes to a significant reduction in the severity of pain, slow progression, improve the functional state of the joints. New variants of their application are presented, based on a clearer understanding of the mechanisms of their action. Further evaluation of these therapies in patients is required.